Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PMV Pharmaceuticals, Inc. (PMVP) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as a Nasdaq Global Select Market registrant. PMV Pharma is a clinical-stage precision oncology company focused on small molecule, tumor-agnostic therapies targeting p53, and its filings offer detailed insight into both financial condition and clinical development activities.
Investors can review current reports on Form 8-K that PMV Pharma files to announce material events. Recent 8-K filings reference press releases for quarterly financial results, including operating expenses, net loss, and cash, cash equivalents, and marketable securities, as well as corporate updates on the PYNNACLE Phase 1/2 trial of rezatapopt (PC14586). Other 8-Ks incorporate investor presentation materials and press releases describing interim Phase 2 data from PYNNACLE and related safe harbor statements.
Alongside 8-Ks, users can access the company’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which are cited in PMV Pharma’s press releases as containing detailed risk factors, financial statements, and discussion of its clinical programs. These periodic reports are central for understanding research and development spending, general and administrative costs, and the company’s assessment of its cash runway as a clinical-stage entity.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as major changes in operating expenses, updates on the PYNNACLE trial, and references to regulatory designations like FDA Fast Track for rezatapopt. Users can also monitor sections related to potential future New Drug Application plans and other regulatory milestones as they are discussed in SEC filings. This page is a practical starting point for analyzing PMVP’s official disclosures, from financial performance to the status of its precision oncology pipeline.
PMV Pharmaceuticals, Inc. Chief Financial Officer Michael Carulli reported an equity compensation grant and updated his share holdings. He received an employee stock option for 240,000 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
The option vests in 48 equal monthly installments beginning on April 5, 2026, which means the award vests gradually over four years. Following this filing, Carulli directly holds 73,848 shares of common stock, which includes 13,702 shares acquired under the company’s Employee Stock Purchase Plan on November 20, 2025.
PMV Pharmaceuticals reported that its General Counsel & COO, Robert Ticktin, received a grant of 319,270 employee stock options. These options give him the right to buy PMV Pharmaceuticals stock in the future, rather than representing shares bought on the open market.
The options were granted at an exercise price listed as $0.0000 per share in the filing and will vest over time. According to the footnote, the award vests in 48 equal monthly installments beginning on April 3, 2026, meaning the executive gains the right to exercise portions of the grant gradually over four years.
PMV Pharmaceuticals, Inc. reported that Chief Development Officer Deepika Jalota received an employee stock option grant. The award covers 303,310 options to purchase company stock and is classified as a grant or award acquisition. According to the terms, these options begin vesting on April 5, 2026, in 48 equal monthly installments, meaning the award vests gradually over four years, which is designed to align the executive’s incentives with the company’s longer-term performance.
PMV Pharmaceuticals, Inc. granted President and CEO David Henry Mack an employee stock option covering 744,960 shares of common stock. The award was reported as an acquisition of derivative securities at a stated price of 0.0000 per share. These options vest in 48 equal monthly installments beginning on April 5, 2026, providing long-term, time-based equity compensation tied to his continued service.
PMV Pharmaceuticals, Inc. reported full-year 2025 results and highlighted progress for its lead p53 reactivator, rezatapopt. The Phase 2 PYNNACLE trial showed a 34% overall response rate among 103 evaluable patients and a 46% response rate in 48 ovarian cancer patients, with responses lasting around 8 months.
Rezatapopt received U.S. FDA Orphan Drug Designation for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancers, and Phase 1 data were published in the New England Journal of Medicine. As of December 31, 2025, PMV held $112.9 million in cash, cash equivalents, and marketable securities, providing expected cash runway to the end of the second quarter of 2027.
Net loss for 2025 was $77.7 million versus $58.7 million in 2024, driven mainly by higher research and development spending of $69.9 million. General and administrative expenses decreased to $16.3 million from $26.9 million, reflecting lower facility and personnel costs after prior-year restructuring.
PMV Pharmaceuticals is a precision oncology company developing small-molecule, tumor-agnostic therapies targeting mutant p53, led by rezatapopt for the p53 Y220C mutation. In the Phase 2 pivotal PYNNACLE trial, rezatapopt achieved a 34% overall response rate in 103 efficacy-evaluable patients and a 46% response rate in 48 ovarian cancer patients, with median response durations of 7.6 and 8.0 months. Rezatapopt has FDA Fast Track and orphan drug designations, and the company plans to submit a New Drug Application for platinum-resistant or refractory TP53 Y220C ovarian cancer in the first quarter of 2027. PMV is also advancing additional p53-focused programs, building companion diagnostics with FoundationOne CDx, and preparing commercialization infrastructure and IP protection around its platform.
PMV Pharmaceuticals’ large shareholder OrbiMed exits its position. OrbiMed Advisors LLC and OrbiMed Capital GP V LLC report that, as of March 2, 2026, they beneficially own 0 shares of PMV common stock, representing 0% of the 53,211,507 shares outstanding.
The exit follows sales by OrbiMed Private Investments V, LP of 505,000 shares on February 27, 2026 and 4,470,291 shares on March 2, 2026, each at a price of $1.62 per share. This amendment is characterized as an exit filing because their ownership fell by more than 1% and below the 5% reporting threshold.
ArrowMark Colorado Holdings, LLC filed an amended beneficial ownership report on PMV Pharmaceuticals, Inc. common stock. The firm reports beneficial ownership of 3,090,093 shares, representing 5.81% of the outstanding common stock as of the event date.
ArrowMark states it has sole voting and dispositive power over all reported shares and no shared power. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PMV Pharmaceuticals.
BML Investment Partners, L.P. filed an amended Schedule 13G reporting its ownership in PMV Pharmaceuticals, Inc.. The fund reports beneficial ownership of 5,292,000 shares of common stock, representing 9.9% of the class as of the event date.
BML has shared voting and dispositive power over all 5,292,000 shares and no sole voting or dispositive power. The filing notes that the securities are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. Braden M. Leonard is deemed an indirect owner through BML Capital Management, LLC, the general partner.
PMV Pharmaceuticals (PMVP) filed its Q3 2025 10‑Q, reporting continued clinical investment and a wider loss as it advances rezatapopt. For the three months ended September 30, 2025, net loss was $21.1 million ($0.40 per share). Operating expenses were $22.5 million, driven by research and development of $18.2 million and general and administrative of $4.3 million. Interest income was $1.5 million.
For the nine months, net loss was $59.7 million, with $56.4 million used in operating cash flow. Cash, cash equivalents, and marketable securities totaled $129.3 million as of September 30, 2025. The company states it has adequate liquidity to operate for the next 12 months. Common shares outstanding were 52,993,238 at quarter‑end; 53,211,507 were outstanding as of November 12, 2025.
PMV reported interim Phase 2 data updates for the PYNNACLE trial of rezatapopt and plans to complete enrollment in the ovarian cohort by the first quarter of 2026, with an NDA submission targeted for the first quarter of 2027. The at‑the‑market program had $113.8 million of capacity remaining, with no sales during the quarter.